<DOC>
	<DOC>NCT01133574</DOC>
	<brief_summary>This is a single rising dose tolerance (Part A) followed by a functional magnetic resonance imaging (Part B)</brief_summary>
	<brief_title>This is a Single Ascending Dose Tolerance Study</brief_title>
	<detailed_description>The Part A of this study is a parallel design followed in a second part by a cross-over design</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Inclusion Criteria BMI 18.0 to 28.0 kg/m2, systolic blood pressure 90140 mmHg, diastolic blood pressure 5090 mmHg, heart rate 50 100 beats/min (all inclusive), clinically normal safety ECG and laboratory results Exclusion Criteria relevant disease, treated with SLV354 before</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Healthy volunteers</keyword>
	<keyword>SLV354</keyword>
	<keyword>Phase I</keyword>
	<keyword>SRDT</keyword>
</DOC>